PFIZER's UNISOM ADVERTISING MOVING TO CLINE, DAVIS & MANN's

PFIZER's UNISOM ADVERTISING MOVING TO CLINE, DAVIS & MANN's new OTC unit effective Dec. 1. The ad agency's new OTC unit will begin official operations that day. In the meantime, the agency said it is hiring staff for the new division. The current ad agency handling the Unisom account is New York-based Avrett, Free & Ginsberg. Cline, Davis & Mann, New York, has appointed Senior VP and Management Supervisor Philip Roselin to manage the new OTC unit. Although staffers currently handling prescription product accounts at the medical specialty agency are expected to work with the new OTC unit, Cline, Davis said it plans to hire both account service personnel as well as creative staff to handle new OTC client accounts. The agency said it is currently in discussions with Pfizer about 1994 marketing plans for Unisom. The agency indicated that the ad campaign for the line, which includes a doxylamine-based sleep aid and a diphenhydramine/acetaminophen sleep aid for pain relief, will include television, radio and print ads. Unisom is currently the OTC division's only account although the agency said it is actively pursuing other OTC drug accounts. Cline, Davis & Mann already handles a number of prescription product accounts for Pfizer including Zithromax, Diflucan, Cardura and Unasyn. In addition, the agency handles professional advertising for Pfizer Consumer Healthcare's Plax mouth rinse. Cline, Davis & Mann also has a number of prescription product accounts with Rhone-Poulenc Rorer, Forest Labs and Parke-Davis.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Ocaliva: Still No Clarity On Why EU Court Opposed Revocation Of Approval

 

Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.

Brazil Pilots Digital Drug Pack Inserts

 

A new pilot aims to take Brazil closer to ‘digital transformation.’

More from Pink Sheet

EUCOPE Wants Simpler Manufacturing Rules And Framework For Combined Trials Under EU Biotech Act

 

EU authorities must “take advantage” of the upcoming Biotech Act to reassess the bloc’s policies and “offset existing challenges” for small and midsized enterprises, trade association EUCOPE has said.

Trial Cancellations And Delays Persist For CROs Amid Biotech Slowdown

 
• By 

The whole contract research organization industry is being impacted by the current volatility in the pharmaceutical industry.

Citeline Japan Awards 2025 - Enter Now!

 

The 14 July deadline for the Citeline Japan Awards 2025 in Tokyo is approaching fast, so here's a reminder to take a look at the categories and criteria and be sure to get your submissions in by this date. Sponsorship opportunities and tables for the event are also available.